(MedPage Today) — A novel drug with the same mechanism as bimekizumab (Bimzelx), but in a smaller molecular package, met its main goals in a phase II study for psoriatic arthritis (PsA), paving the way for registration trials.
Called sonelokimab…
Source link : https://www.medpagetoday.com/rheumatology/arthritis/117855
Author :
Publish date : 2025-10-08 20:42:00
Copyright for syndicated content belongs to the linked Source.
